Medpage Today on MSN17h
Gene-Editing Therapy Reduced Attacks in Hereditary Angioedema
A single dose of the CRISPR-based gene-editing therapy NTLA-2002 reduced angioedema attacks and led to sustained reduction in ...
CRISPR-Cas9 gene editing trial results support further development as treatment for hereditary angioedema
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...
Intellia slips after mid-stage data for CRISPR-based hereditary angioedema therapy
Intellia Therapeutics (NTLA) stock fell ~9% in reaction to Phase 2 trial data for a CRISPR-based gene editing therapy for ...
BioPharma Dive4h
Intellia data spark debate about CRISPR drug’s potential
Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...
healthday5h
ACAAI: Gene-Editing Therapy Reduces Angioedema Attacks in Hereditary Angioedema
For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...
FierceBiotech3h
Poseida's HAE gene therapy edits primate livers and reduces kallikrein protein levels in mice, company says
Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing ...
Poseida Therapeutics to present data on P-KLKB1-101 in hereditary angioedema
Poseida Therapeutics (PSTX) announced the upcoming presentation of new preclinical data supporting the potential of P-KLKB1-101, a ...
technologynetworks5h
CRISPR-Cas9 Therapy Shows Promise As Single-Dose Treatment for Hereditary Angioedema
Researchers expand on their phase one study demonstrating a single treatment with a CRISPR-Cas9-based gene editing therapy, ...
Intellia Therapeutics presents results from Phase 2 study of NTLA-2002
Intellia Therapeutics (NTLA) announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary ...
Armed robbery in Revesby9h
CRISPR-Cas9 Phase 2 Boosts Hereditary Angioedema Hope
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...
EurekAlert!8h
Phase Two results with CRISPR-Cas9 gene editing support further development as treatment for hereditary angioedema (HAE)
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...